Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains? [Yahoo! Finance]
Iovance Biotherapeutics (IOVA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.
Iovance Biotherapeutics (IOVA) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback [Seeking Alpha]